Top

Published in:

Open Access 01-06-2017

Platelet-activating factor podoplanin: from discovery to drug development

Authors: Ai Takemoto, Kenichi Miyata, Naoya Fujita

Published in: Cancer and Metastasis Reviews | Issue 2/2017

Abstract

Tumor cell-induced platelet aggregation facilitates hematogenous metastasis by promoting tumor embolization, preventing immunological assaults and shear stress, and the platelet-releasing growth factors support tumor growth and invasion. Podoplanin, also known as Aggrus, is a type I transmembrane mucin-like glycoprotein and is expressed on wide range of tumor cells. Podoplanin has a role in platelet aggregation and metastasis formation through the binding to its platelet receptor, C-type lectin-like receptor 2 (CLEC-2). The podoplanin research was originally started from the cloning of highly metastatic NL-17 subclone from mouse colon 26 cancer cell line and from the establishment of 8F11 monoclonal antibody (mAb) that could neutralize NL-17-induced platelet aggregation and hematogenous metastasis. Later on, podoplanin was identified as the antigen of 8F11 mAb, and its ectopic expression brought to cells the platelet-aggregating abilities and hematogenous metastasis phenotypes. From the 8F11 mAb recognition epitopes, podoplanin is found to contain tandemly repeated, highly conserved motifs, designated platelet aggregation-stimulating (PLAG) domains. Series of analyses using the cells expressing the mutants and the established neutralizing anti-podoplanin mAbs uncovered that both PLAG3 and PLAG4 domains are associated with the CLEC-2 binding. The neutralizing mAbs targeting PLAG3 or PLAG4 could suppress podoplanin-induced platelet aggregation and hematogenous metastasis through inhibiting the podoplanin–CLEC-2 binding. Therefore, these domains are certainly functional in podoplanin-mediated metastasis through its platelet-aggregating activity. This review summarizes the platelet functions in metastasis formation, the role of platelet aggregation-inducing factor podoplanin in pathological and physiological situations, and the possibility to develop podoplanin-targeting drugs in the future.

Menter, D. G., Tucker, S. C., Kopetz, S., Sood, A. K., Crissman, J. D., & Honn, K. V. (2014). Platelets and cancer: a casual or causal relationship: revisited. Cancer and Metastasis Reviews, 33(1), 231–269. doi:10.1007/s10555-014-9498-0.CrossRefPubMedPubMedCentral

Gay, L. J., & Felding-Habermann, B. (2011). Contribution of platelets to tumour metastasis. Nature Reviews: Cancer, 11(2), 123–134. doi:10.1038/nrc3004.PubMed

Key, N. S., Khorana, A. A., Mackman, N., McCarty, O. J., White, G. C., Francis, C. W., et al. (2016). Thrombosis in cancer: research priorities identified by a National Cancer Institute/National Heart, Lung, and Blood Institute Strategic Working Group. Cancer Research, 76(13), 3671–3675. doi:10.1158/0008-5472.CAN-15-3100.CrossRefPubMed

Mehta, P. (1984). Potential role of platelets in the pathogenesis of tumor metastasis. Blood, 63(1), 55–63.PubMed

Tsuruo, T., Iida, H., Makishima, F., Yamori, T., Kawabata, H., Tsukagoshi, S., et al. (1985). Inhibition of spontaneous and experimental tumor metastasis by the calcium antagonist verapamil. Cancer Chemotherapy and Pharmacology, 14(1), 30–33.CrossRefPubMed

Algra, A. M., & Rothwell, P. M. (2012). Effects of regular aspirin on long-term cancer incidence and metastasis: a systematic comparison of evidence from observational studies versus randomised trials. Lancet Oncology, 13(5), 518–527. doi:10.1016/S1470-2045(12)70112-2.CrossRefPubMed

Rothwell, P. M., Fowkes, F. G., Belch, J. F., Ogawa, H., Warlow, C. P., & Meade, T. W. (2011). Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 377(9759), 31–41. doi:10.1016/S0140-6736(10)62110-1.CrossRefPubMed

Tsuruo, T., Yamori, T., Naganuma, K., Tsukagoshi, S., & Sakurai, Y. (1983). Characterization of metastatic clones derived from a metastatic variant of mouse colon adenocarcinoma 26. Cancer Research, 43(11), 5437–5442.PubMed

Mahalingam, M., Ugen, K. E., Kao, K. J., & Klein, P. A. (1988). Functional role of platelets in experimental metastasis studied with cloned murine fibrosarcoma cell variants. Cancer Research, 48(6), 1460–1464.PubMed

10.

Fidler, I. J. (2003). The pathogenesis of cancer metastasis: the ‘seed and soil’ hypothesis revisited. Nature Reviews: Cancer, 3(6), 453–458. doi:10.1038/nrc1098.PubMed

11.

Nieswandt, B., Hafner, M., Echtenacher, B., & Mannel, D. N. (1999). Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Research, 59(6), 1295–1300.PubMed

12.

Placke, T., Salih, H. R., & Kopp, H. G. (2012). GITR ligand provided by thrombopoietic cells inhibits NK cell antitumor activity. Journal of Immunology, 189(1), 154–160. doi:10.4049/jimmunol.1103194.CrossRef

13.

Placke, T., Orgel, M., Schaller, M., Jung, G., Rammensee, H. G., Kopp, H. G., et al. (2012). Platelet-derived MHC class I confers a pseudonormal phenotype to cancer cells that subverts the antitumor reactivity of natural killer immune cells. Cancer Research, 72(2), 440–448. doi:10.1158/0008-5472.CAN-11-1872.CrossRefPubMed

14.

Gersuk, G. M., Westermark, B., Mohabeer, A. J., Challita, P. M., Pattamakom, S., & Pattengale, P. K. (1991). Inhibition of human natural killer cell activity by platelet-derived growth factor (PDGF)III. Membrane binding studies and differential biological effect of recombinant PDGF isoforms. Scandinavian Journal of Immunology, 33(5), 521–532.CrossRefPubMed

15.

Kopp, H. G., Placke, T., & Salih, H. R. (2009). Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity. Cancer Research, 69(19), 7775–7783. doi:10.1158/0008-5472.CAN-09-2123.CrossRefPubMed

16.

Schumacher, D., Strilic, B., Sivaraj, K. K., Wettschureck, N., & Offermanns, S. (2013). Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. Cancer Cell, 24(1), 130–137. doi:10.1016/j.ccr.2013.05.008.CrossRefPubMed

17.

Labelle, M., Begum, S., & Hynes, R. O. (2014). Platelets guide the formation of early metastatic niches. Proceedings of the National Academy of Sciences of the United States of America, 111(30), E3053–E3061. doi:10.1073/pnas.1411082111.CrossRefPubMedPubMedCentral

18.

Labelle, M., Begum, S., & Hynes, R. O. (2011). Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. Cancer Cell, 20(5), 576–590. doi:10.1016/j.ccr.2011.09.009.CrossRefPubMedPubMedCentral

19.

Takemoto, A., Okitaka, M., Takagi, S., Takami, M., Sato, S., Nishio, M., et al. (2017). A critical role of platelet TGF-beta release in podoplanin-mediated tumour invasion and metastasis. Scientific Reports, 7, 42186. doi:10.1038/srep42186.CrossRefPubMedPubMedCentral

20.

Boucharaba, A., Serre, C. M., Gres, S., Saulnier-Blache, J. S., Bordet, J. C., Guglielmi, J., et al. (2004). Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. Journal of Clinical Investigation, 114(12), 1714–1725. doi:10.1172/JCI22123.CrossRefPubMedPubMedCentral

21.

Watanabe, M., Okochi, E., Sugimoto, Y., & Tsuruo, T. (1988). Identification of a platelet-aggregating factor of murine colon adenocarcinoma 26: Mr 44,000 membrane protein as determined by monoclonal antibodies. Cancer Research, 48(22), 6411–6416.PubMed

22.

Watanabe, M., Sugimoto, Y., & Tsuruo, T. (1990). Expression of a Mr 41,000 glycoprotein associated with thrombin-independent platelet aggregation in high metastatic variants of murine B16 melanoma. Cancer Research, 50(20), 6657–6662.PubMed

23.

Sugimoto, Y., Watanabe, M., Oh-hara, T., Sato, S., Isoe, T., & Tsuruo, T. (1991). Suppression of experimental lung colonization of a metastatic variant of murine colon adenocarcinoma 26 by a monoclonal antibody 8F11 inhibiting tumor cell-induced platelet aggregation. Cancer Research, 51(3), 921–925.PubMed

24.

Toyoshima, M., Nakajima, M., Yamori, T., & Tsuruo, T. (1995). Purification and characterization of the platelet-aggregating sialoglycoprotein gp44 expressed by highly metastatic variant cells of mouse colon adenocarcinoma 26. Cancer Research, 55(4), 767–773.PubMed

25.

Kato, Y., Fujita, N., Kunita, A., Sato, S., Kaneko, M., Osawa, M., et al. (2003). Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors. Journal of Biological Chemistry, 278(51), 51599–51605. doi:10.1074/jbc.M309935200.CrossRefPubMed

26.

Kaneko, M. K., Kato, Y., Kitano, T., & Osawa, M. (2006). Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor. Gene, 378, 52–57. doi:10.1016/j.gene.2006.04.023.CrossRefPubMed

27.

Ma, T., Yang, B., Matthay, M. A., & Verkman, A. S. (1998). Evidence against a role of mouse, rat, and two cloned human t1alpha isoforms as a water channel or a regulator of aquaporin-type water channels. American Journal of Respiratory Cell and Molecular Biology, 19(1), 143–149. doi:10.1165/ajrcmb.19.1.2953.CrossRefPubMed

28.

Zimmer, G., Lottspeich, F., Maisner, A., Klenk, H. D., & Herrler, G. (1997). Molecular characterization of gp40, a mucin-type glycoprotein from the apical plasma membrane of Madin-Darby canine kidney cells (type I). Biochemical Journal, 326(Pt 1), 99–108.CrossRefPubMedPubMedCentral

29.

Zimmer, G., Oeffner, F., Von Messling, V., Tschernig, T., Groness, H. J., Klenk, H. D., et al. (1999). Cloning and characterization of gp36, a human mucin-type glycoprotein preferentially expressed in vascular endothelium. Biochemical Journal, 341(Pt 2), 277–284.CrossRefPubMedPubMedCentral

30.

Nose, K., Saito, H., & Kuroki, T. (1990). Isolation of a gene sequence induced later by tumor-promoting 12-O-tetradecanoylphorbol-13-acetate in mouse osteoblastic cells (MC3T3-E1) and expressed constitutively in ras-transformed cells. Cell Growth and Differentiation, 1(11), 511–518.PubMed

31.

Farr, A. G., Berry, M. L., Kim, A., Nelson, A. J., Welch, M. P., & Aruffo, A. (1992). Characterization and cloning of a novel glycoprotein expressed by stromal cells in T-dependent areas of peripheral lymphoid tissues. Journal of Experimental Medicine, 176(5), 1477–1482.CrossRefPubMed

32.

Schacht, V., Dadras, S. S., Johnson, L. A., Jackson, D. G., Hong, Y. K., & Detmar, M. (2005). Up-regulation of the lymphatic marker podoplanin, a mucin-type transmembrane glycoprotein, in human squamous cell carcinomas and germ cell tumors. American Journal of Pathology, 166(3), 913–921. doi:10.1016/S0002-9440(10)62311-5.CrossRefPubMedPubMedCentral

33.

Gandarillas, A., Scholl, F. G., Benito, N., Gamallo, C., & Quintanilla, M. (1997). Induction of PA2.26, a cell-surface antigen expressed by active fibroblasts, in mouse epidermal keratinocytes during carcinogenesis. Molecular Carcinogenesis, 20(1), 10–18.CrossRefPubMed

34.

Breiteneder-Geleff, S., Soleiman, A., Kowalski, H., Horvat, R., Amann, G., Kriehuber, E., et al. (1999). Angiosarcomas express mixed endothelial phenotypes of blood and lymphatic capillaries: podoplanin as a specific marker for lymphatic endothelium. American Journal of Pathology, 154(2), 385–394. doi:10.1016/S0002-9440(10)65285-6.CrossRefPubMedPubMedCentral

35.

Rishi, A. K., Joyce-Brady, M., Fisher, J., Dobbs, L. G., Floros, J., VanderSpek, J., et al. (1995). Cloning, characterization, and development expression of a rat lung alveolar type I cell gene in embryonic endodermal and neural derivatives. Developmental Biology, 167(1), 294–306.CrossRefPubMed

36.

Breiteneder-Geleff, S., Matsui, K., Soleiman, A., Meraner, P., Poczewski, H., Kalt, R., et al. (1997). Podoplanin, novel 43-kd membrane protein of glomerular epithelial cells, is down-regulated in puromycin nephrosis. American Journal of Pathology, 151(4), 1141–1152.PubMedPubMedCentral

37.

Malhotra, D., Fletcher, A. L., Astarita, J., Lukacs-Kornek, V., Tayalia, P., Gonzalez, S. F., et al. (2012). Transcriptional profiling of stroma from inflamed and resting lymph nodes defines immunological hallmarks. Nature Immunology, 13(5), 499–510. doi:10.1038/ni.2262.CrossRefPubMedPubMedCentral

38.

Shibahara, J., Kashima, T., Kikuchi, Y., Kunita, A., & Fukayama, M. (2006). Podoplanin is expressed in subsets of tumors of the central nervous system. Virchows Archiv, 448(4), 493–499. doi:10.1007/s00428-005-0133-x.CrossRefPubMed

39.

Mahtab, E. A., Wijffels, M. C., Van Den Akker, N. M., Hahurij, N. D., Lie-Venema, H., Wisse, L. J., et al. (2008). Cardiac malformations and myocardial abnormalities in podoplanin knockout mouse embryos: correlation with abnormal epicardial development. Developmental Dynamics, 237(3), 847–857. doi:10.1002/dvdy.21463.CrossRefPubMed

40.

Ramirez, M. I., Millien, G., Hinds, A., Cao, Y., Seldin, D. C., & Williams, M. C. (2003). T1alpha, a lung type I cell differentiation gene, is required for normal lung cell proliferation and alveolus formation at birth. Developmental Biology, 256(1), 61–72.CrossRefPubMed

41.

Schacht, V., Ramirez, M. I., Hong, Y. K., Hirakawa, S., Feng, D., Harvey, N., et al. (2003). T1alpha/podoplanin deficiency disrupts normal lymphatic vasculature formation and causes lymphedema. EMBO Journal, 22(14), 3546–3556. doi:10.1093/emboj/cdg342.CrossRefPubMedPubMedCentral

42.

Uhrin, P., Zaujec, J., Breuss, J. M., Olcaydu, D., Chrenek, P., Stockinger, H., et al. (2010). Novel function for blood platelets and podoplanin in developmental separation of blood and lymphatic circulation. Blood, 115(19), 3997–4005. doi:10.1182/blood-2009-04-216069.CrossRefPubMed

43.

Hess, P. R., Rawnsley, D. R., Jakus, Z., Yang, Y., Sweet, D. T., Fu, J., et al. (2014). Platelets mediate lymphovenous hemostasis to maintain blood-lymphatic separation throughout life. Journal of Clinical Investigation, 124(1), 273–284. doi:10.1172/JCI70422.CrossRefPubMed

44.

Herzog, B. H., Fu, J., Wilson, S. J., Hess, P. R., Sen, A., McDaniel, J. M., et al. (2013). Podoplanin maintains high endothelial venule integrity by interacting with platelet CLEC-2. Nature, 502(7469), 105–109. doi:10.1038/nature12501.CrossRefPubMedPubMedCentral

45.

Acton, S. E., Farrugia, A. J., Astarita, J. L., Mourao-Sa, D., Jenkins, R. P., Nye, E., et al. (2014). Dendritic cells control fibroblastic reticular network tension and lymph node expansion. Nature, 514(7523), 498–502. doi:10.1038/nature13814.CrossRefPubMedPubMedCentral

46.

Tamura, S., Suzuki-Inoue, K., Tsukiji, N., Shirai, T., Sasaki, T., Osada, M., et al. (2016). Podoplanin-positive periarteriolar stromal cells promote megakaryocyte growth and proplatelet formation in mice by CLEC-2. Blood, 127(13), 1701–1710. doi:10.1182/blood-2015-08-663708.CrossRefPubMed

47.

Hatakeyama, K., Kaneko, M. K., Kato, Y., Ishikawa, T., Nishihira, K., Tsujimoto, Y., et al. (2012). Podoplanin expression in advanced atherosclerotic lesions of human aortas. Thrombosis Research, 129(4), e70–e76. doi:10.1016/j.thromres.2012.01.003.CrossRefPubMed

48.

Peters, A., Pitcher, L. A., Sullivan, J. M., Mitsdoerffer, M., Acton, S. E., Franz, B., et al. (2011). Th17 cells induce ectopic lymphoid follicles in central nervous system tissue inflammation. Immunity, 35(6), 986–996. doi:10.1016/j.immuni.2011.10.015.CrossRefPubMedPubMedCentral

49.

Peterziel, H., Muller, J., Danner, A., Barbus, S., Liu, H. K., Radlwimmer, B., et al. (2012). Expression of podoplanin in human astrocytic brain tumors is controlled by the PI3K-AKT-AP-1 signaling pathway and promoter methylation. Neuro-Oncology, 14(4), 426–439. doi:10.1093/neuonc/nos055.CrossRefPubMedPubMedCentral

50.

Kunita, A., Kashima, T. G., Ohazama, A., Grigoriadis, A. E., & Fukayama, M. (2011). Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. American Journal of Pathology, 179(2), 1041–1049. doi:10.1016/j.ajpath.2011.04.027.CrossRefPubMedPubMedCentral

51.

Takagi, S., Oh-hara, T., Sato, S., Gong, B., Takami, M., & Fujita, N. (2014). Expression of Aggrus/podoplanin in bladder cancer and its role in pulmonary metastasis. International Journal of Cancer, 134(11), 2605–2614. doi:10.1002/ijc.28602.CrossRefPubMed

52.

Kimura, N., & Kimura, I. (2005). Podoplanin as a marker for mesothelioma. Pathology International, 55(2), 83–86. doi:10.1111/j.1440-1827.2005.01791.x.CrossRefPubMed

53.

Kato, Y., Sasagawa, I., Kaneko, M., Osawa, M., Fujita, N., & Tsuruo, T. (2004). Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors. Oncogene, 23(52), 8552–8556. doi:10.1038/sj.onc.1207869.CrossRefPubMed

54.

Hisakane, K., Saruwatari, K., Fujii, S., Kirita, K., Umemura, S., Matsumoto, S., et al. (2016). Unique intravascular tumor microenvironment predicting recurrence of lung squamous cell carcinoma. Journal of Cancer Research and Clinical Oncology, 142(3), 593–600. doi:10.1007/s00432-015-2068-1.CrossRefPubMed

55.

Mishima, K., Kato, Y., Kaneko, M. K., Nishikawa, R., Hirose, T., & Matsutani, M. (2006). Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathologica, 111(5), 483–488. doi:10.1007/s00401-006-0063-y.CrossRefPubMed

56.

Mishima, K., Kato, Y., Kaneko, M. K., Nakazawa, Y., Kunita, A., Fujita, N., et al. (2006). Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma. Acta Neuropathologica, 111(6), 563–568. doi:10.1007/s00401-006-0033-4.CrossRefPubMed

57.

Yuan, P., Temam, S., El-Naggar, A., Zhou, X., Liu, D. D., Lee, J. J., et al. (2006). Overexpression of podoplanin in oral cancer and its association with poor clinical outcome. Cancer, 107(3), 563–569. doi:10.1002/cncr.22061.CrossRefPubMed

58.

Kawase, A., Ishii, G., Nagai, K., Ito, T., Nagano, T., Murata, Y., et al. (2008). Podoplanin expression by cancer associated fibroblasts predicts poor prognosis of lung adenocarcinoma. International Journal of Cancer, 123(5), 1053–1059. doi:10.1002/ijc.23611.CrossRefPubMed

59.

Hoshino, A., Ishii, G., Ito, T., Aoyagi, K., Ohtaki, Y., Nagai, K., et al. (2011). Podoplanin-positive fibroblasts enhance lung adenocarcinoma tumor formation: podoplanin in fibroblast functions for tumor progression. Cancer Research, 71(14), 4769–4779. doi:10.1158/0008-5472.CAN-10-3228.CrossRefPubMed

60.

Pula, B., Jethon, A., Piotrowska, A., Gomulkiewicz, A., Owczarek, T., Calik, J., et al. (2011). Podoplanin expression by cancer-associated fibroblasts predicts poor outcome in invasive ductal breast carcinoma. Histopathology, 59(6), 1249–1260. doi:10.1111/j.1365-2559.2011.04060.x.CrossRefPubMed

61.

Yurugi, Y., Wakahara, M., Matsuoka, Y., Sakabe, T., Kubouchi, Y., Haruki, T., et al. (2017). Podoplanin expression in cancer-associated fibroblasts predicts poor prognosis in patients with squamous cell carcinoma of the lung. Anticancer Research, 37(1), 207–213. doi:10.21873/anticanres.11308.CrossRefPubMed

62.

Yoshida, T., Ishii, G., Goto, K., Neri, S., Hashimoto, H., Yoh, K., et al. (2015). Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Clinical Cancer Research, 21(3), 642–651. doi:10.1158/1078-0432.CCR-14-0846.CrossRefPubMed

63.

Hatzioannou, A., Nayar, S., Gaitanis, A., Barone, F., Anagnostopoulos, C., & Verginis, P. (2016). Intratumoral accumulation of podoplanin-expressing lymph node stromal cells promote tumor growth through elimination of CD4+ tumor-infiltrating lymphocytes. Oncoimmunology, 5(9), e1216289. doi:10.1080/2162402X.2016.1216289.CrossRefPubMedPubMedCentral

64.

Suzuki, H., Onimaru, M., Koga, T., Takeshita, M., Yano, T., Maehara, Y., et al. (2011). High podoplanin expression in cancer cells predicts lower incidence of nodal metastasis in patients with lung squamous cell carcinoma. Pathology, Research and Practice, 207(2), 111–115. doi:10.1016/j.prp.2010.11.006.CrossRefPubMed

65.

Ito, T., Ishii, G., Nagai, K., Nagano, T., Kojika, M., Murata, Y., et al. (2009). Low podoplanin expression of tumor cells predicts poor prognosis in pathological stage IB squamous cell carcinoma of the lung, tissue microarray analysis of 136 patients using 24 antibodies. Lung Cancer, 63(3), 418–424. doi:10.1016/j.lungcan.2008.06.008.CrossRefPubMed

66.

Ikoma, Y., Kijima, H., Masuda, R., Tanaka, M., Inokuchi, S., & Iwazaki, M. (2015). Podoplanin expression is correlated with the prognosis of lung squamous cell carcinoma. Biomedical Research (Tokyo, Japan), 36(6), 393–402. doi:10.2220/biomedres.36.393.CrossRef

67.

Kunita, A., Kashima, T. G., Morishita, Y., Fukayama, M., Kato, Y., Tsuruo, T., et al. (2007). The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis. American Journal of Pathology, 170(4), 1337–1347. doi:10.2353/ajpath.2007.060790.CrossRefPubMedPubMedCentral

68.

Takagi, S., Takemoto, A., Takami, M., Oh-Hara, T., & Fujita, N. (2014). Platelets promote osteosarcoma cell growth through activation of the platelet-derived growth factor receptor-Akt signaling axis. Cancer Science, 105(8), 983–988. doi:10.1111/cas.12464.CrossRefPubMedPubMedCentral

69.

Miyata, K., Takemoto, A., Okumura, S., Nishio, M., & Fujita, N. (2017) Podoplanin enhances lung cancer cell growth in vivo by inducing platelet aggregation. Scientific Reports, 7, 4059. doi:10.1038/s41598-017-04324-1.

70.

Wicki, A., Lehembre, F., Wick, N., Hantusch, B., Kerjaschki, D., & Christofori, G. (2006). Tumor invasion in the absence of epithelial-mesenchymal transition: podoplanin-mediated remodeling of the actin cytoskeleton. Cancer Cell, 9(4), 261–272. doi:10.1016/j.ccr.2006.03.010.CrossRefPubMed

71.

Kaneko, M., Kato, Y., Kunita, A., Fujita, N., Tsuruo, T., & Osawa, M. (2004). Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells. Journal of Biological Chemistry, 279(37), 38838–38843. doi:10.1074/jbc.M407210200.CrossRefPubMed

72.

Kaneko, M. K., Kato, Y., Kameyama, A., Ito, H., Kuno, A., Hirabayashi, J., et al. (2007). Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor. FEBS Letters, 581(2), 331–336. doi:10.1016/j.febslet.2006.12.044.CrossRefPubMed

73.

Amano, K., Chiba, Y., Kasahara, Y., Kato, Y., Kaneko, M. K., Kuno, A., et al. (2008). Engineering of mucin-type human glycoproteins in yeast cells. Proceedings of the National Academy of Sciences of the United States of America, 105(9), 3232–3237. doi:10.1073/pnas.0710412105.CrossRefPubMedPubMedCentral

74.

Nagae, M., Morita-Matsumoto, K., Kato, M., Kaneko, M. K., Kato, Y., & Yamaguchi, Y. (2014). A platform of C-type lectin-like receptor CLEC-2 for binding O-glycosylated podoplanin and nonglycosylated rhodocytin. Structure, 22(12), 1711–1721. doi:10.1016/j.str.2014.09.009.CrossRefPubMed

75.

Sekiguchi, T., Takemoto, A., Takagi, S., Takatori, K., Sato, S., Takami, M., et al. (2016). Targeting a novel domain in podoplanin for inhibiting platelet-mediated tumor metastasis. Oncotarget, 7(4), 3934–3946. doi:10.18632/oncotarget.6598.CrossRefPubMed

76.

Huang, T. F., Liu, C. Z., & Yang, S. H. (1995). Aggretin, a novel platelet-aggregation inducer from snake (Calloselasma rhodostoma) venom, activates phospholipase C by acting as a glycoprotein Ia/IIa agonist. Biochemical Journal, 309(Pt 3), 1021–1027.CrossRefPubMedPubMedCentral

77.

Suzuki-Inoue, K., Fuller, G. L., Garcia, A., Eble, J. A., Pohlmann, S., Inoue, O., et al. (2006). A novel Syk-dependent mechanism of platelet activation by the C-type lectin receptor CLEC-2. Blood, 107(2), 542–549. doi:10.1182/blood-2005-05-1994.CrossRefPubMed

78.

Suzuki-Inoue, K., Kato, Y., Inoue, O., Kaneko, M. K., Mishima, K., Yatomi, Y., et al. (2007). Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells. Journal of Biological Chemistry, 282(36), 25993–26001. doi:10.1074/jbc.M702327200.CrossRefPubMed

79.

Christou, C. M., Pearce, A. C., Watson, A. A., Mistry, A. R., Pollitt, A. Y., Fenton-May, A. E., et al. (2008). Renal cells activate the platelet receptor CLEC-2 through podoplanin. Biochemical Journal, 411(1), 133–140. doi:10.1042/BJ20071216.CrossRefPubMedPubMedCentral

80.

Fuller, G. L., Williams, J. A., Tomlinson, M. G., Eble, J. A., Hanna, S. L., Pohlmann, S., et al. (2007). The C-type lectin receptors CLEC-2 and Dectin-1, but not DC-SIGN, signal via a novel YXXL-dependent signaling cascade. Journal of Biological Chemistry, 282(17), 12397–12409. doi:10.1074/jbc.M609558200.CrossRefPubMedPubMedCentral

81.

Kerrigan, A. M., Dennehy, K. M., Mourao-Sa, D., Faro-Trindade, I., Willment, J. A., Taylor, P. R., et al. (2009). CLEC-2 is a phagocytic activation receptor expressed on murine peripheral blood neutrophils. Journal of Immunology, 182(7), 4150–4157. doi:10.4049/jimmunol.0802808.CrossRef

82.

Colonna, M., Samaridis, J., & Angman, L. (2000). Molecular characterization of two novel C-type lectin-like receptors, one of which is selectively expressed in human dendritic cells. European Journal of Immunology, 30(2), 697–704. doi:10.1002/1521-4141(200002)30:2<697::AID-IMMU697>3.0.CO;2-M.CrossRefPubMed

83.

Chang, C. H., Chung, C. H., Hsu, C. C., Huang, T. Y., & Huang, T. F. (2010). A novel mechanism of cytokine release in phagocytes induced by aggretin, a snake venom C-type lectin protein, through CLEC-2 ligation. Journal of Thrombosis and Haemostasis, 8(11), 2563–2570. doi:10.1111/j.1538-7836.2010.04045.x.CrossRefPubMed

84.

Mourao-Sa, D., Robinson, M. J., Zelenay, S., Sancho, D., Chakravarty, P., Larsen, R., et al. (2011). CLEC-2 signaling via Syk in myeloid cells can regulate inflammatory responses. European Journal of Immunology, 41(10), 3040–3053. doi:10.1002/eji.201141641.CrossRefPubMed

85.

Acton, S. E., Astarita, J. L., Malhotra, D., Lukacs-Kornek, V., Franz, B., Hess, P. R., et al. (2012). Podoplanin-rich stromal networks induce dendritic cell motility via activation of the C-type lectin receptor CLEC-2. Immunity, 37(2), 276–289. doi:10.1016/j.immuni.2012.05.022.CrossRefPubMedPubMedCentral

86.

Suzuki-Inoue, K., Inoue, O., Ding, G., Nishimura, S., Hokamura, K., Eto, K., et al. (2010). Essential in vivo roles of the C-type lectin receptor CLEC-2: embryonic/neonatal lethality of CLEC-2-deficient mice by blood/lymphatic misconnections and impaired thrombus formation of CLEC-2-deficient platelets. Journal of Biological Chemistry, 285(32), 24494–24507. doi:10.1074/jbc.M110.130575.CrossRefPubMedPubMedCentral

87.

Osada, M., Inoue, O., Ding, G., Shirai, T., Ichise, H., Hirayama, K., et al. (2012). Platelet activation receptor CLEC-2 regulates blood/lymphatic vessel separation by inhibiting proliferation, migration, and tube formation of lymphatic endothelial cells. Journal of Biological Chemistry, 287(26), 22241–22252. doi:10.1074/jbc.M111.329987.CrossRefPubMedPubMedCentral

88.

Kato, Y., Kaneko, M. K., Kuno, A., Uchiyama, N., Amano, K., Chiba, Y., et al. (2006). Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain. Biochemical and Biophysical Research Communications, 349(4), 1301–1307. doi:10.1016/j.bbrc.2006.08.171.CrossRefPubMed

89.

Miyata, K., Takagi, S., Sato, S., Morioka, H., Shiba, K., Minamisawa, T., et al. (2014). Suppression of Aggrus/podoplanin-induced platelet aggregation and pulmonary metastasis by a single-chain antibody variable region fragment. Cancer Medicine, 3(6), 1595–1604. doi:10.1002/cam4.320.CrossRefPubMedPubMedCentral

90.

Nakazawa, Y., Takagi, S., Sato, S., Oh-hara, T., Koike, S., Takami, M., et al. (2011). Prevention of hematogenous metastasis by neutralizing mice and its chimeric anti-Aggrus/podoplanin antibodies. Cancer Science, 102(11), 2051–2057. doi:10.1111/j.1349-7006.2011.02058.x.CrossRefPubMed

91.

Takagi, S., Sato, S., Oh-hara, T., Takami, M., Koike, S., Mishima, Y., et al. (2013). Platelets promote tumor growth and metastasis via direct interaction between Aggrus/podoplanin and CLEC-2. PloS One, 8(8), e73609. doi:10.1371/journal.pone.0073609.CrossRefPubMedPubMedCentral

92.

Kato, Y., Kaneko, M. K., Kunita, A., Ito, H., Kameyama, A., Ogasawara, S., et al. (2008). Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2. Cancer Science, 99(1), 54–61. doi:10.1111/j.1349-7006.2007.00634.x.PubMed

93.

Kato, Y., Kaneko, M., Sata, M., Fujita, N., Tsuruo, T., & Osawa, M. (2005). Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma. Tumour Biology, 26(4), 195–200. doi:10.1159/000086952.CrossRefPubMed

94.

Kato, Y., Kunita, A., Abe, S., Ogasawara, S., Fujii, Y., Oki, H., et al. (2015). The chimeric antibody chLpMab-7 targeting human podoplanin suppresses pulmonary metastasis via ADCC and CDC rather than via its neutralizing activity. Oncotarget, 6(34), 36003–36018. doi:10.18632/oncotarget.5339.PubMedPubMedCentral

95.

Kato, Y., Kunita, A., Fukayama, M., Abe, S., Nishioka, Y., Uchida, H., et al. (2017). Antiglycopeptide mouse monoclonal antibody LpMab-21 exerts antitumor activity against human podoplanin through antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity. Monoclon Antib Immunodiagn Immunother, 36(1), 20–24. doi:10.1089/mab.2016.0045.PubMed

96.

Kato, Y., & Kaneko, M. K. (2014). A cancer-specific monoclonal antibody recognizes the aberrantly glycosylated podoplanin. Scientific Reports, 4, 5924. doi:10.1038/srep05924.CrossRefPubMedPubMedCentral

97.

Kaneko, M. K., Oki, H., Ogasawara, S., Takagi, M., & Kato, Y. (2015). Anti-podoplanin monoclonal antibody LpMab-7 detects metastatic lesions of osteosarcoma. Monoclon Antib Immunodiagn Immunother, 34(3), 154–161. doi:10.1089/mab.2014.0091.PubMed

98.

Chang, Y. W., Hsieh, P. W., Chang, Y. T., Lu, M. H., Huang, T. F., Chong, K. Y., et al. (2015). Identification of a novel platelet antagonist that binds to CLEC-2 and suppresses podoplanin-induced platelet aggregation and cancer metastasis. Oncotarget, 6(40), 42733–42748. doi:10.18632/oncotarget.5811.CrossRefPubMedPubMedCentral

99.

Shirai, T., Inoue, O., Tamura, S., Tsukiji, N., Sasaki, T., Endo, H., et al. (2017). C-type lectin-like receptor 2 promotes hematogenous tumor metastasis and prothrombotic state in tumor-bearing mice. Journal of Thrombosis and Haemostasis, 15(3), 513–525. doi:10.1111/jth.13604.CrossRefPubMed

Title: Platelet-activating factor podoplanin: from discovery to drug development
Authors: Ai Takemoto
Kenichi Miyata
Naoya Fujita
Publication date: 01-06-2017
Publisher: Springer US
Published in: Cancer and Metastasis Reviews / Issue 2/2017
Print ISSN: 0167-7659
Electronic ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-017-9672-2

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 2/2017

Platelet “first responders” in wound response, cancer, and metastasis

Preface

Biography—David Menter

Platelets, circulating tumor cells, and the circulome

Cleavage and phosphorylation: important post-translational modifications of galectin-3

The potential role of platelets in the consensus molecular subtypes of colorectal cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer